Epidemiologic features of non-alcoholic fatty liver disease in Russia

Epidemiologic features of non-alcoholic fatty liver disease in Russia

Aim of investigation. To estimate prevalence nonalcoholic fatty liver disease (NAFLD) with assessment of age dynamics of distribution, interrelation of stages and value of clinical cardio-vascular markers in patients addressing for medical aid to physicians of polyclinics of Russia.Material and meth...

Full description

Saved in:

Bibliographic Details
Main Authors:	O. M. Drapkina, V. T. Ivashkin
Format:	Article
Language:	Russian
Published:	Gastro LLC 2014-10-01
Series:	Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:	non-alcoholic fatty liver disease metabolic syndrome obesity non-alcoholic steatohepatitis systemic hypertension dyslipidemia
Online Access:	https://www.gastro-j.ru/jour/article/view/1126
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Jessica M. Rubino, et al.
Published: (2025-01-01)

Methodical approaches in experimental modelling of non-alcoholic fatty liver disease
by: N. V. Bivalkevich, et al.
Published: (2015-09-01)

Combination of autoimmune hepatitis to non-alcoholic steatohepatitis (Clinical case)
by: A. A. Driga, et al.
Published: (2010-11-01)

Prevalence and factors associated with non-alcoholic fatty liver disease among women with polycystic ovary syndrome
by: Maria Elisa Franciscatto, et al.
Published: (2025-01-01)

Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease
by: Roger F. Butterworth, et al.
Published: (2019-03-01)

Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results
by: V. T. Ivashkin, et al.
Published: (2015-12-01)

Non-Alcoholic Fatty Liver Disease, Bile Acids and Intestinal Microbiota
by: R. V. Maslennikov, et al.
Published: (2018-09-01)

The Safety and Efficacy of Dietary Epigallocatechin Gallate Supplementation for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: Recent Updates
by: Ruike Yan, et al.
Published: (2025-01-01)

Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
by: D. V. Garbuzenko
Published: (2022-01-01)

Liver and Nutrition. An Optimal Diet for Non-Alcoholic Fatty Liver Disease
by: M. V. Mayevskaya, et al.
Published: (2018-11-01)

Prevalence of non-alcoholic fatty liver disease at obesity and its interrelation with cardio-vascular disease and 2nd type diabetes mellitus risk factors
by: G. A. Melnichenko, et al.
Published: (2012-04-01)

Two faces of the same coin non alcoholic fatty liver disease; with and without diabetes: Comparative clinico pathological analysis: A cross sectional observational study
by: Syed Mushfiq, et al.
Published: (2025-01-01)

Profile of Children With Non-alcoholic Fatty Liver Disease Referred to a Hospital in Iran
by: Amin Ghanbari, et al.
Published: (2024-12-01)

Practical Aspects of Clinical Manifestations, Pathogenesis and Therapy of Alcoholic Liver Disease and Non-alcoholic Fatty Liver Disease: Expert Opinion
by: V. V. Tsukanov, et al.
Published: (2023-11-01)

Application of ursodeoxycholic acid at non-alcoholic and alcohol-induced steatohepatitis
by: Ye. A. Fedos’ina, et al.
Published: (2010-06-01)

Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease
by: V. T. Ivashkin, et al.
Published: (2022-12-01)

Improvement of non-alcoholic fatty liver disease treatment
by: P. I. Seliverstov, et al.
Published: (2014-10-01)

Prevalence and association of non-alcoholic fatty liver disease and insulin resistance among non-diabetic obese, overweight, and metabolically obese normal-weight adult patients attending at a tertiary care hospital in Eastern India
by: Samik Pramanik, et al.
Published: (2025-02-01)

Detectability of Liver Steatosis and Fibrosis with Transient Elastography and Controlled Attenuation Parameter in Residents of St. Petersburg
by: V. P. Kovyazina, et al.
Published: (2021-04-01)

Intrahepatic Cholestasis in Non-Alcoholic Fatty Liver Disease: Pathogenesis and Role of Ademetionine in Treatment
by: Ye. N. Shirokova
Published: (2023-08-01)

Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia
by: Masahiro Kikuchi, et al.
Published: (2024-09-01)

Non-Alcoholic Fatty Liver Disease in Cardiac Patients with Overweight and Obesity
by: I. V. Logacheva, et al.
Published: (2019-01-01)

Risk of Cirrhosis in Patients with Non-alcoholic Fatty Liver Disease and Previous Viral Hepatitis B
by: S. N. Batskikh, et al.
Published: (2020-09-01)

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
by: K. L. Raikhelson, et al.
Published: (2024-05-01)

Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
by: A. E. Bagriy, et al.
Published: (2021-06-01)

Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease
by: Yuan-Yuan Xu, et al.
Published: (2024-09-01)

An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study
by: M. V. Mayevskaya, et al.
Published: (2020-01-01)

Metabolic and Genetic Determinants of Lipid Metabolism Disruption in Non-Alcoholic Fatty Liver Disease
by: O. Yu. Kytikova, et al.
Published: (2020-05-01)

Ultrasound radiomics-based logistic regression model for fibrotic NASH
by: Fei Xia, et al.
Published: (2025-02-01)

The Role of the Microbiome and Intestinal Mucosal Barrier in the Development and Progression of Non-Alcoholic Fatty Liver Disease
by: T. S. Krolevets, et al.
Published: (2020-12-01)

Clinical and Pathogenetic Parallels of Nonalcoholic Fatty Liver Disease and Gallstone Disease
by: Aleksey O. Bueverov
Published: (2019-03-01)

Global research trends in Chinese medicine for the treatment of non-alcoholic fatty liver disease (NAFLD): A bibliometric study
by: Kangjie li, et al.
Published: (2025-03-01)

Perioperative treatment with cilostazol reverses steatosis and improves liver regeneration after major hepatectomy in a steatotic rat model
by: Sebastian Holländer, et al.
Published: (2025-01-01)

Pathogenic role of lipids in non-alcoholic fatty liver disease
by: Yu. O. Shulpekova
Published: (2012-02-01)

FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
by: Muhammad Mazhar Azam, et al.
Published: (2024-12-01)

Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review
by: Hongcai Li, et al.
Published: (2025-02-01)

The rationale for the aggressive progression of MASLD in patients with type 2 diabetes
by: Valeria Michelle Fernández-Garibay, et al.
Published: (2025-01-01)

Association between non-alcoholic fatty liver disease and progression of abdominal aortic aneurysm: a multicenter study
by: Ximing Wang, et al.
Published: (2025-01-01)

Antioxidants in the Treatment of Chronic Diffuse Liver Diseases (the Results of the “MAXAR” Observational Program)
by: M. V. Mayevskaya, et al.
Published: (2018-11-01)

Phenotypes of Non-Alcoholic Fatty Liver Disease in Different Regions of the Russian Federation, Diagnostic and Therapeutic Approach in Clinical Practice
by: V. T. Ivashkin, et al.
Published: (2023-08-01)